← Back to Search

Medication and Therapy for Obsessive-Compulsive Disorder

Stanford University, Stanford, CA
Pharmacotherapy +1 moreN/AWaitlist AvailableLed by Carolyn Rodriguez, MD, PhDResearch Sponsored by Stanford University

Study Summary

This trial is for OCD patients who have completed a different study protocol and are now looking for aftercare treatment options.

Eligible Conditions
  • Obsessive-Compulsive Disorder


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 14 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 14 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Improvement in the severity of OCD symptoms as measured by the Yale-Brown Obsessive Compulsive Scale (YBOCS)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Active Control
Group I: PharmacotherapyActive Control1 Intervention
Participants will receive pharmacotherapy by a psychiatrist
Group II: PsychotherapyActive Control1 Intervention
Participants will receive evidenced based psychotherapy by a trained psychologist

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,322 Previous Clinical Trials
17,287,620 Total Patients Enrolled
13 Trials studying Obsessive-Compulsive Disorder
1,216 Patients Enrolled for Obsessive-Compulsive Disorder
Carolyn Rodriguez, MD, PhDPrincipal Investigator - Assistant Professor, Stanford University
Stanford University
4 Previous Clinical Trials
56 Total Patients Enrolled
1 Trials studying Obsessive-Compulsive Disorder
40 Patients Enrolled for Obsessive-Compulsive Disorder

Media Library

Pharmacotherapy Clinical Trial Eligibility Overview. Trial Name: NCT03511534 — N/A
Obsessive-Compulsive Disorder Research Study Groups: Pharmacotherapy, Psychotherapy
Obsessive-Compulsive Disorder Clinical Trial 2023: Pharmacotherapy Highlights & Side Effects. Trial Name: NCT03511534 — N/A
Pharmacotherapy 2023 Treatment Timeline for Medical Study. Trial Name: NCT03511534 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is recruitment for this experiment still ongoing?

"Affirmative. The records posted on clinicaltrials.gov reveal that this research project, which was initially established in June 2017, is actively enrolling new participants. At present, 200 patients need to be recruited from a single site."

Answered by AI

How many participants have been accepted into this clinical investigation?

"Yes, the information on clinicaltrials.gov denotes that this medical trial is actively enrolling. The project was first posted on June 23rd 2017 and most recently revised on May 13th 2020. This study seeks to recruit 200 participants from a single site."

Answered by AI
~38 spots leftby Jun 2025